Summary

Global Non-small Cell Lung Cancer Drugs Market 2023-2027
The non-small cell lung cancer drugs market is forecasted to grow by USD 15936.89 mn during 2022-2027, accelerating at a CAGR of 9.25% during the forecast period. The report on the non-small cell lung cancer drugs market provides a holistic analysis, market size, and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence and incidence of non-small cell lung cancer, the strong drug pipeline and recent drug approvals, and the availability of patient assistance programs.
Technavio's non-small cell lung cancer drugs market is segmented as below:
By Type
• Adenocarcinoma
• Squamous cell carcinoma
• Large cell carcinoma
By Product
• Biologics
• Small molecule targeted therapy
• Chemotherapy
By Geographical Landscape
• North America
• Europe
• Asia
• Rest of World (ROW)
This study identifies the introduction and approval of combination therapies as one of the prime reasons driving the non-small cell lung cancer drugs market growth during the next few years. Also, an increase in strategic alliances to develop non-small cell lung cancer drugs and the use of predictive biomarkers for the development of cost-effective therapies will lead to sizable demand in the market.
The report on the non-small cell lung cancer drugs market covers the following areas:
• Non-small cell lung cancer drugs market sizing
• Non-small cell lung cancer drugs market forecast
• Non-small cell lung cancer drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading non-small cell lung cancer drugs market vendors that include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BeiGene Ltd., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck KGaA, Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., PharmaMar SA, Regeneron Pharmaceuticals Inc., Sanofi, and Takeda Pharmaceutical Co. Ltd.. Also, the non-small cell lung cancer drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit - https://www.technavio.com/report/non-small-cell-lung-cancer-drugs-market-industry-analysis
The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

ページTOPに戻る

Table of Contents

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary - Chart on Market Overview
o Exhibit 02: Executive Summary - Data Table on Market Overview
o Exhibit 03: Executive Summary - Chart on Global Market Characteristics
o Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
o Exhibit 06: Executive Summary - Chart on Market Segmentation by Product
o Exhibit 07: Executive Summary - Chart on Incremental Growth
o Exhibit 08: Executive Summary - Data Table on Incremental Growth
o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global non-small cell lung cancer drugs market 2017 - 2021
o Exhibit 18: Historic Market Size - Data Table on global non-small cell lung cancer drugs market 2017 - 2021 ($ million)
o 4.2 Type Segment Analysis 2017 - 2021
o Exhibit 19: Historic Market Size - Type Segment 2017 - 2021 ($ million)
o 4.3 Product Segment Analysis 2017 - 2021
o Exhibit 20: Historic Market Size - Product Segment 2017 - 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 - 2021
o Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
o 4.5 Country Segment Analysis 2017 - 2021
o Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
• 6 Market Segmentation by Type
o 6.1 Market segments
o Exhibit 30: Chart on Type - Market share 2022-2027 (%)
o Exhibit 31: Data Table on Type - Market share 2022-2027 (%)
o 6.2 Comparison by Type
o Exhibit 32: Chart on Comparison by Type
o Exhibit 33: Data Table on Comparison by Type
o 6.3 Adenocarcinoma - Market size and forecast 2022-2027
o Exhibit 34: Chart on Adenocarcinoma - Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Adenocarcinoma - Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Adenocarcinoma - Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Adenocarcinoma - Year-over-year growth 2022-2027 (%)
o 6.4 Squamous cell carcinoma - Market size and forecast 2022-2027
o Exhibit 38: Chart on Squamous cell carcinoma - Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Squamous cell carcinoma - Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Squamous cell carcinoma - Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Squamous cell carcinoma - Year-over-year growth 2022-2027 (%)
o 6.5 Large cell carcinoma - Market size and forecast 2022-2027
o Exhibit 42: Chart on Large cell carcinoma - Market size and forecast 2022-2027 ($ million)
o Exhibit 43: Data Table on Large cell carcinoma - Market size and forecast 2022-2027 ($ million)
o Exhibit 44: Chart on Large cell carcinoma - Year-over-year growth 2022-2027 (%)
o Exhibit 45: Data Table on Large cell carcinoma - Year-over-year growth 2022-2027 (%)
o 6.6 Market opportunity by Type
o Exhibit 46: Market opportunity by Type ($ million)
o Exhibit 47: Data Table on Market opportunity by Type ($ million)
• 7 Market Segmentation by Product
o 7.1 Market segments
o Exhibit 48: Chart on Product - Market share 2022-2027 (%)
o Exhibit 49: Data Table on Product - Market share 2022-2027 (%)
o 7.2 Comparison by Product
o Exhibit 50: Chart on Comparison by Product
o Exhibit 51: Data Table on Comparison by Product
o 7.3 Biologics - Market size and forecast 2022-2027
o Exhibit 52: Chart on Biologics - Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Data Table on Biologics - Market size and forecast 2022-2027 ($ million)
o Exhibit 54: Chart on Biologics - Year-over-year growth 2022-2027 (%)
o Exhibit 55: Data Table on Biologics - Year-over-year growth 2022-2027 (%)
o 7.4 Small molecule targeted therapy - Market size and forecast 2022-2027
o Exhibit 56: Chart on Small molecule targeted therapy - Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Data Table on Small molecule targeted therapy - Market size and forecast 2022-2027 ($ million)
o Exhibit 58: Chart on Small molecule targeted therapy - Year-over-year growth 2022-2027 (%)
o Exhibit 59: Data Table on Small molecule targeted therapy - Year-over-year growth 2022-2027 (%)
o 7.5 Chemotherapy - Market size and forecast 2022-2027
o Exhibit 60: Chart on Chemotherapy - Market size and forecast 2022-2027 ($ million)
o Exhibit 61: Data Table on Chemotherapy - Market size and forecast 2022-2027 ($ million)
o Exhibit 62: Chart on Chemotherapy - Year-over-year growth 2022-2027 (%)
o Exhibit 63: Data Table on Chemotherapy - Year-over-year growth 2022-2027 (%)
o 7.6 Market opportunity by Product
o Exhibit 64: Market opportunity by Product ($ million)
o Exhibit 65: Data Table on Market opportunity by Product ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 67: Chart on Market share By Geographical Landscape 2022-2027 (%)
o Exhibit 68: Data Table on Market share By Geographical Landscape 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 69: Chart on Geographic comparison
o Exhibit 70: Data Table on Geographic comparison
o 9.3 North America - Market size and forecast 2022-2027
o Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
o Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
o Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
o Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
o 9.4 Europe - Market size and forecast 2022-2027
o Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
o Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
o Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
o Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
o 9.5 Asia - Market size and forecast 2022-2027
o Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
o Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
o Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
o Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
o Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
o Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
o Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
o Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
o 9.7 US - Market size and forecast 2022-2027
o Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
o Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
o Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
o Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
o 9.8 Germany - Market size and forecast 2022-2027
o Exhibit 91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
o Exhibit 92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
o Exhibit 93: Chart on Germany - Year-over-year growth 2022-2027 (%)
o Exhibit 94: Data Table on Germany - Year-over-year growth 2022-2027 (%)
o 9.9 China - Market size and forecast 2022-2027
o Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
o Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
o Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
o Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)
o 9.10 Canada - Market size and forecast 2022-2027
o Exhibit 99: Chart on Canada - Market size and forecast 2022-2027 ($ million)
o Exhibit 100: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
o Exhibit 101: Chart on Canada - Year-over-year growth 2022-2027 (%)
o Exhibit 102: Data Table on Canada - Year-over-year growth 2022-2027 (%)
o 9.11 UK - Market size and forecast 2022-2027
o Exhibit 103: Chart on UK - Market size and forecast 2022-2027 ($ million)
o Exhibit 104: Data Table on UK - Market size and forecast 2022-2027 ($ million)
o Exhibit 105: Chart on UK - Year-over-year growth 2022-2027 (%)
o Exhibit 106: Data Table on UK - Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 107: Market opportunity By Geographical Landscape ($ million)
o Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 109: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 111: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 112: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 113: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 114: Matrix on vendor position and classification
o 12.3 AbbVie Inc.
o Exhibit 115: AbbVie Inc. - Overview
o Exhibit 116: AbbVie Inc. - Product / Service
o Exhibit 117: AbbVie Inc. - Key news
o Exhibit 118: AbbVie Inc. - Key offerings
o 12.4 Amgen Inc.
o Exhibit 119: Amgen Inc. - Overview
o Exhibit 120: Amgen Inc. - Product / Service
o Exhibit 121: Amgen Inc. - Key offerings
o 12.5 Astellas Pharma Inc.
o Exhibit 122: Astellas Pharma Inc. - Overview
o Exhibit 123: Astellas Pharma Inc. - Product / Service
o Exhibit 124: Astellas Pharma Inc. - Key news
o Exhibit 125: Astellas Pharma Inc. - Key offerings
o 12.6 AstraZeneca PLC
o Exhibit 126: AstraZeneca PLC - Overview
o Exhibit 127: AstraZeneca PLC - Product / Service
o Exhibit 128: AstraZeneca PLC - Key news
o Exhibit 129: AstraZeneca PLC - Key offerings
o 12.7 Bayer AG
o Exhibit 130: Bayer AG - Overview
o Exhibit 131: Bayer AG - Business segments
o Exhibit 132: Bayer AG - Key news
o Exhibit 133: Bayer AG - Key offerings
o Exhibit 134: Bayer AG - Segment focus
o 12.8 BeiGene Ltd.
o Exhibit 135: BeiGene Ltd. - Overview
o Exhibit 136: BeiGene Ltd. - Business segments
o Exhibit 137: BeiGene Ltd. - Key offerings
o Exhibit 138: BeiGene Ltd. - Segment focus
o 12.9 Boehringer Ingelheim International GmbH
o Exhibit 139: Boehringer Ingelheim International GmbH - Overview
o Exhibit 140: Boehringer Ingelheim International GmbH - Business segments
o Exhibit 141: Boehringer Ingelheim International GmbH - Key news
o Exhibit 142: Boehringer Ingelheim International GmbH - Key offerings
o Exhibit 143: Boehringer Ingelheim International GmbH - Segment focus
o 12.10 Bristol Myers Squibb Co.
o Exhibit 144: Bristol Myers Squibb Co. - Overview
o Exhibit 145: Bristol Myers Squibb Co. - Product / Service
o Exhibit 146: Bristol Myers Squibb Co. - Key news
o Exhibit 147: Bristol Myers Squibb Co. - Key offerings
o 12.11 Eli Lilly and Co.
o Exhibit 148: Eli Lilly and Co. - Overview
o Exhibit 149: Eli Lilly and Co. - Product / Service
o Exhibit 150: Eli Lilly and Co. - Key news
o Exhibit 151: Eli Lilly and Co. - Key offerings
o 12.12 F. Hoffmann La Roche Ltd.
o Exhibit 152: F. Hoffmann La Roche Ltd. - Overview
o Exhibit 153: F. Hoffmann La Roche Ltd. - Business segments
o Exhibit 154: F. Hoffmann La Roche Ltd. - Key news
o Exhibit 155: F. Hoffmann La Roche Ltd. - Key offerings
o Exhibit 156: F. Hoffmann La Roche Ltd. - Segment focus
o 12.13 Innovent Biologics Inc.
o Exhibit 157: Innovent Biologics Inc. - Overview
o Exhibit 158: Innovent Biologics Inc. - Product / Service
o Exhibit 159: Innovent Biologics Inc. - Key offerings
o 12.14 Merck KGaA
o Exhibit 160: Merck KGaA - Overview
o Exhibit 161: Merck KGaA - Business segments
o Exhibit 162: Merck KGaA - Key news
o Exhibit 163: Merck KGaA - Key offerings
o Exhibit 164: Merck KGaA - Segment focus
o 12.15 Ono Pharmaceutical Co. Ltd.
o Exhibit 165: Ono Pharmaceutical Co. Ltd. - Overview
o Exhibit 166: Ono Pharmaceutical Co. Ltd. - Product / Service
o Exhibit 167: Ono Pharmaceutical Co. Ltd. - Key offerings
o 12.16 Pfizer Inc.
o Exhibit 168: Pfizer Inc. - Overview
o Exhibit 169: Pfizer Inc. - Product / Service
o Exhibit 170: Pfizer Inc. - Key news
o Exhibit 171: Pfizer Inc. - Key offerings
o 12.17 Takeda Pharmaceutical Co. Ltd.
o Exhibit 172: Takeda Pharmaceutical Co. Ltd. - Overview
o Exhibit 173: Takeda Pharmaceutical Co. Ltd. - Product / Service
o Exhibit 174: Takeda Pharmaceutical Co. Ltd. - Key news
o Exhibit 175: Takeda Pharmaceutical Co. Ltd. - Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 176: Inclusions checklist
o Exhibit 177: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 178: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 179: Research methodology
o Exhibit 180: Validation techniques employed for market sizing
o Exhibit 181: Information sources
o 13.5 List of abbreviations
o Exhibit 182: List of abbreviations


Exhibits:
Exhibits1: Executive Summary - Chart on Market Overview
Exhibits2: Executive Summary - Data Table on Market Overview
Exhibits3: Executive Summary - Chart on Global Market Characteristics
Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits5: Executive Summary - Chart on Market Segmentation by Type
Exhibits6: Executive Summary - Chart on Market Segmentation by Product
Exhibits7: Executive Summary - Chart on Incremental Growth
Exhibits8: Executive Summary - Data Table on Incremental Growth
Exhibits9: Executive Summary - Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size - Data Table on global non-small cell lung cancer drugs market 2017 - 2021 ($ million)
Exhibits19: Historic Market Size - Type Segment 2017 - 2021 ($ million)
Exhibits20: Historic Market Size - Product Segment 2017 - 2021 ($ million)
Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
Exhibits23: Five forces analysis - Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition - Five forces 2022 and 2027
Exhibits30: Chart on Type - Market share 2022-2027 (%)
Exhibits31: Data Table on Type - Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Type
Exhibits33: Data Table on Comparison by Type
Exhibits34: Chart on Adenocarcinoma - Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Adenocarcinoma - Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Adenocarcinoma - Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Adenocarcinoma - Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Squamous cell carcinoma - Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Squamous cell carcinoma - Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Squamous cell carcinoma - Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Squamous cell carcinoma - Year-over-year growth 2022-2027 (%)
Exhibits42: Chart on Large cell carcinoma - Market size and forecast 2022-2027 ($ million)
Exhibits43: Data Table on Large cell carcinoma - Market size and forecast 2022-2027 ($ million)
Exhibits44: Chart on Large cell carcinoma - Year-over-year growth 2022-2027 (%)
Exhibits45: Data Table on Large cell carcinoma - Year-over-year growth 2022-2027 (%)
Exhibits46: Market opportunity by Type ($ million)
Exhibits47: Data Table on Market opportunity by Type ($ million)
Exhibits48: Chart on Product - Market share 2022-2027 (%)
Exhibits49: Data Table on Product - Market share 2022-2027 (%)
Exhibits50: Chart on Comparison by Product
Exhibits51: Data Table on Comparison by Product
Exhibits52: Chart on Biologics - Market size and forecast 2022-2027 ($ million)
Exhibits53: Data Table on Biologics - Market size and forecast 2022-2027 ($ million)
Exhibits54: Chart on Biologics - Year-over-year growth 2022-2027 (%)
Exhibits55: Data Table on Biologics - Year-over-year growth 2022-2027 (%)
Exhibits56: Chart on Small molecule targeted therapy - Market size and forecast 2022-2027 ($ million)
Exhibits57: Data Table on Small molecule targeted therapy - Market size and forecast 2022-2027 ($ million)
Exhibits58: Chart on Small molecule targeted therapy - Year-over-year growth 2022-2027 (%)
Exhibits59: Data Table on Small molecule targeted therapy - Year-over-year growth 2022-2027 (%)
Exhibits60: Chart on Chemotherapy - Market size and forecast 2022-2027 ($ million)
Exhibits61: Data Table on Chemotherapy - Market size and forecast 2022-2027 ($ million)
Exhibits62: Chart on Chemotherapy - Year-over-year growth 2022-2027 (%)
Exhibits63: Data Table on Chemotherapy - Year-over-year growth 2022-2027 (%)
Exhibits64: Market opportunity by Product ($ million)
Exhibits65: Data Table on Market opportunity by Product ($ million)
Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits67: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits68: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits69: Chart on Geographic comparison
Exhibits70: Data Table on Geographic comparison
Exhibits71: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibits72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibits73: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibits74: Data Table on North America - Year-over-year growth 2022-2027 (%)
Exhibits75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits77: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibits78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
Exhibits79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits81: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibits82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
Exhibits83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits87: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibits88: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibits89: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibits90: Data Table on US - Year-over-year growth 2022-2027 (%)
Exhibits91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits93: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibits94: Data Table on Germany - Year-over-year growth 2022-2027 (%)
Exhibits95: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibits96: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibits97: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibits98: Data Table on China - Year-over-year growth 2022-2027 (%)
Exhibits99: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibits100: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibits101: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibits102: Data Table on Canada - Year-over-year growth 2022-2027 (%)
Exhibits103: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibits104: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibits105: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibits106: Data Table on UK - Year-over-year growth 2022-2027 (%)
Exhibits107: Market opportunity By Geographical Landscape ($ million)
Exhibits108: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits109: Impact of drivers and challenges in 2022 and 2027
Exhibits110: Overview on Criticality of inputs and Factors of differentiation
Exhibits111: Overview on factors of disruption
Exhibits112: Impact of key risks on business
Exhibits113: Vendors covered
Exhibits114: Matrix on vendor position and classification
Exhibits115: AbbVie Inc. - Overview
Exhibits116: AbbVie Inc. - Product / Service
Exhibits117: AbbVie Inc. - Key news
Exhibits118: AbbVie Inc. - Key offerings
Exhibits119: Amgen Inc. - Overview
Exhibits120: Amgen Inc. - Product / Service
Exhibits121: Amgen Inc. - Key offerings
Exhibits122: Astellas Pharma Inc. - Overview
Exhibits123: Astellas Pharma Inc. - Product / Service
Exhibits124: Astellas Pharma Inc. - Key news
Exhibits125: Astellas Pharma Inc. - Key offerings
Exhibits126: AstraZeneca PLC - Overview
Exhibits127: AstraZeneca PLC - Product / Service
Exhibits128: AstraZeneca PLC - Key news
Exhibits129: AstraZeneca PLC - Key offerings
Exhibits130: Bayer AG - Overview
Exhibits131: Bayer AG - Business segments
Exhibits132: Bayer AG - Key news
Exhibits133: Bayer AG - Key offerings
Exhibits134: Bayer AG - Segment focus
Exhibits135: BeiGene Ltd. - Overview
Exhibits136: BeiGene Ltd. - Business segments
Exhibits137: BeiGene Ltd. - Key offerings
Exhibits138: BeiGene Ltd. - Segment focus
Exhibits139: Boehringer Ingelheim International GmbH - Overview
Exhibits140: Boehringer Ingelheim International GmbH - Business segments
Exhibits141: Boehringer Ingelheim International GmbH - Key news
Exhibits142: Boehringer Ingelheim International GmbH - Key offerings
Exhibits143: Boehringer Ingelheim International GmbH - Segment focus
Exhibits144: Bristol Myers Squibb Co. - Overview
Exhibits145: Bristol Myers Squibb Co. - Product / Service
Exhibits146: Bristol Myers Squibb Co. - Key news
Exhibits147: Bristol Myers Squibb Co. - Key offerings
Exhibits148: Eli Lilly and Co. - Overview
Exhibits149: Eli Lilly and Co. - Product / Service
Exhibits150: Eli Lilly and Co. - Key news
Exhibits151: Eli Lilly and Co. - Key offerings
Exhibits152: F. Hoffmann La Roche Ltd. - Overview
Exhibits153: F. Hoffmann La Roche Ltd. - Business segments
Exhibits154: F. Hoffmann La Roche Ltd. - Key news
Exhibits155: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits156: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits157: Innovent Biologics Inc. - Overview
Exhibits158: Innovent Biologics Inc. - Product / Service
Exhibits159: Innovent Biologics Inc. - Key offerings
Exhibits160: Merck KGaA - Overview
Exhibits161: Merck KGaA - Business segments
Exhibits162: Merck KGaA - Key news
Exhibits163: Merck KGaA - Key offerings
Exhibits164: Merck KGaA - Segment focus
Exhibits165: Ono Pharmaceutical Co. Ltd. - Overview
Exhibits166: Ono Pharmaceutical Co. Ltd. - Product / Service
Exhibits167: Ono Pharmaceutical Co. Ltd. - Key offerings
Exhibits168: Pfizer Inc. - Overview
Exhibits169: Pfizer Inc. - Product / Service
Exhibits170: Pfizer Inc. - Key news
Exhibits171: Pfizer Inc. - Key offerings
Exhibits172: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibits173: Takeda Pharmaceutical Co. Ltd. - Product / Service
Exhibits174: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibits175: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibits176: Inclusions checklist
Exhibits177: Exclusions checklist
Exhibits178: Currency conversion rates for US$
Exhibits179: Research methodology
Exhibits180: Validation techniques employed for market sizing
Exhibits181: Information sources
Exhibits182: List of abbreviations